A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA



Status:Not yet recruiting
Conditions:Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - Any
Updated:4/5/2019
Start Date:April 4, 2019
End Date:October 15, 2020
Contact:There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Email:clinicaltrials.gov@lilly.com
Phone:1-317-615-4559

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA

This study evaluates the safety and efficacy of baricitinib in participants with primary
biliary cholangitis (PBC) who do not respond or are unable to take ursodeoxycholic acid
(UDCA).


Inclusion Criteria:

- Have a diagnosis of PBC (consistent with American Association for the Study of Liver
Disease [AASLD] and European Association for Study of the Liver [EASL] Practice
Guidelines; as demonstrated by the presence of at least 2 of the following 3
diagnostic factors:

- History of elevated ALP levels for at least 6 months

- Positive antimitochondrial antibodies titer

- Liver biopsy consistent with PBC

- Have ALP ≥1.67 x ULN but <6 x ULN.

- Taking UDCA for at least 52 weeks (stable dose for at least 12 weeks) prior to Week 0,
or have previously taken, but are intolerant (in the opinion of the investigator) to
UDCA and have not received UDCA for at least 12 weeks prior to Week 0.

- Nonpregnant, nonbreastfeeding female participants of childbearing potential.

Exclusion Criteria:

- History or presence of other concomitant liver diseases including:

- Hepatitis C virus (HCV) infection

- Hepatitis B virus (HBV) infection

- Primary sclerosing cholangitis

- Alcoholic liver disease

- Autoimmune liver disease other than PBC, such as overlap hepatitis

- Nonalcoholic steatohepatitis

- Gilbert's syndrome

- Presence of clinical complications of PBC or clinically significant hepatic
decompensation, including:

- Liver transplantation, current placement on a liver transplant list or current
Model for End Stage Liver Disease (MELD) score ≥15

- Portal hypertension with complications, including known gastric or esophageal
varices, ascites, history of variceal bleeds or related therapeutic or
prophylactic interventions (e.g., beta blockers, insertion of variceal bands or
transjugular intrahepatic portosystemic shunt), or hepatic encephalopathy

- Cirrhosis, including history or presence of one or more of the following:

- spontaneous bacterial peritonitis

- hepatocellular carcinoma

- Hepatorenal syndrome (type I or II)

- Have an estimated glomerular filtration rate (eGFR) based on the most recent available
serum creatinine of <90 milliliters/minute/1.73 m2.

- Have screening electrocardiogram (ECG) abnormalities that in the opinion of the
investigator or the sponsor are clinically significant and indicate an unacceptable
risk for the participant's participation in the study.

- Have experienced any of the following within 12 weeks of screening: myocardial
infarction, unstable ischemic heart disease, stroke, or New York Heart Association
Stage III/IV heart failure.

- Have a history of venous thromboembolism (VTE) (deep vein thrombosis/pulmonary
embolism [DVT/PE]).

- Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal,
endocrine, hematological, neurological, or neuropsychiatric disorders or any other
serious and/or unstable illness that, in the opinion of the investigator, could
constitute an unacceptable risk when taking investigational product or interfere with
the interpretation of data.

- Have a current or recent (<4 weeks prior to randomization) clinically serious
infection or any other active or recent infection that, in the opinion of the
investigator, would pose an unacceptable risk to the participant if participating in
the study.

- Have had symptomatic herpes zoster infection within 12 weeks prior to randomization.

- Have active tuberculosis (TB) disease determined on the basis of a positive medical
history, physical examination, or chest radiography (per local standard of care) or
latent TB infection (LTBI).

- Have any of the following specific abnormalities based on screening central lab test
results:

- Hemoglobin <10 grams per deciliter (100.0 grams per liter)

- Alanine aminotransferase (ALT) >3 x ULN

- aspartate aminotransferase (AST) >3 x ULN

- alkaline phosphatase (ALP) >6 x ULN

- Total bilirubin level (TBL) >ULN

- Creatine phosphokinase (CPK) > ULN

- Serum albumin < lower limit of normal (LLN)

- International Normalized Ratio of Prothrombin Time (INR) > ULN

- Total white blood cell (WBC) count
- Absolute neutrophil count [ANC]
- Lymphocyte count
- Platelet (thrombocyte) count
- Are receiving unstable treatment for pruritus within 6 weeks prior to Week 0.

- Have been treated with systemic (oral or parenteral) corticosteroids within 6 weeks
prior to Week 0.

- Have received biologic treatments for an immunologic disease within 4 weeks of
screening.

- Have received a Janus kinase (JAK) inhibitor.

- Have received obeticholic acid.

- Have received fenofibrate or other fibrates for the treatment of PBC.
We found this trial at
14
sites
Rochester, Minnesota 55905
Principal Investigator: John Eaton
Phone: 507-284-3917
?
mi
from
Rochester, MN
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Principal Investigator: John Vierling
Phone: 713-798-1966
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Alexander Kuo
Phone: 310-423-6000
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Aurora, Colorado 80045
Principal Investigator: Lisa Forman
Phone: 728-848-2292
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Baltimore, Maryland 21202
Principal Investigator: Paul Thuluvath
Phone: 410-332-9356
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Bologna, BO 40138
Principal Investigator: Marco Lenzi
Phone: 390512145224
?
mi
from
Bologna,
Click here to add this to my saved trials
11100 Euclid Avenue
Cleveland, Ohio 44106
Principal Investigator: Anthony Post
Phone: 216-844-5387
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Coronado, California 92118
Principal Investigator: Tarek Hassanein
Phone: 619-522-0399
?
mi
from
Coronado, CA
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Principal Investigator: Stuart Gordon
Phone: 313-916-9465
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Lakewood Ranch, Florida 34211
Principal Investigator: Guy W Neff
Phone: 941-727-7772
?
mi
from
Lakewood Ranch, FL
Click here to add this to my saved trials
Miami, Florida 33136
Principal Investigator: Cynthia Levy
Phone: 305-243-4615
?
mi
from
Miami, FL
Click here to add this to my saved trials
New Orleans, Louisiana 70112
Principal Investigator: Fredric Regenstein
Phone: 504-988-5344
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
Sacramento, California 95817
Principal Investigator: Christopher Bowlus
Phone: 916-734-8696
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63104
Principal Investigator: Bruce Bacon
Phone: 314-577-8764
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials